AR123706A1 - Moduladores del regulador de conductancia transmembranario de la fibrosis quística - Google Patents

Moduladores del regulador de conductancia transmembranario de la fibrosis quística

Info

Publication number
AR123706A1
AR123706A1 ARP210102776A ARP210102776A AR123706A1 AR 123706 A1 AR123706 A1 AR 123706A1 AR P210102776 A ARP210102776 A AR P210102776A AR P210102776 A ARP210102776 A AR P210102776A AR 123706 A1 AR123706 A1 AR 123706A1
Authority
AR
Argentina
Prior art keywords
modulators
cystic fibrosis
conductance regulator
transmembrane conductance
pharmaceutical compositions
Prior art date
Application number
ARP210102776A
Other languages
English (en)
Inventor
Jason Mcartney
Alexander Russell Abela
Sunny Abraham
Corey Don Anderson
Vijayalaksmi Arumugam
Jaclyn Chau
Jeremy Clemens
Thomas Cleveland
Timothy Richard Coon
Timothy A Dwight
Bryan A Frieman
Peter Fallecido Grootenhuis
Ruah Sara Sabina Hadida
Yoshihiro Ishihara
Haripada Khatuya
Paul Krenitsky
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Alina Silina
Joe A Tran
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR123706A1 publication Critical patent/AR123706A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.
ARP210102776A 2020-10-07 2021-10-07 Moduladores del regulador de conductancia transmembranario de la fibrosis quística AR123706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063088759P 2020-10-07 2020-10-07

Publications (1)

Publication Number Publication Date
AR123706A1 true AR123706A1 (es) 2023-01-04

Family

ID=78463975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102776A AR123706A1 (es) 2020-10-07 2021-10-07 Moduladores del regulador de conductancia transmembranario de la fibrosis quística

Country Status (6)

Country Link
US (1) US20230374038A1 (es)
EP (1) EP4225761A1 (es)
AR (1) AR123706A1 (es)
TW (1) TW202229299A (es)
UY (1) UY39458A (es)
WO (1) WO2022076620A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
JP2023537944A (ja) 2020-08-13 2023-09-06 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレーターの結晶形態
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
PE20250606A1 (es) * 2022-04-06 2025-02-26 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
JP2025517322A (ja) 2022-05-16 2025-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
JP2025529476A (ja) 2022-09-15 2025-09-04 イドルシア・ファーマシューティカルズ・リミテッド （３Ｓ，７Ｓ，１０Ｒ，１３Ｒ）－１３－ベンジル－２０－フルオロ－７－イソブチル－Ｎ－（２－（３－メトキシ－１，２，４－オキサジアゾール－５－イル）エチル）－６，９－ジメチル－１，５，８，１１－テトラオキソ－１０－（２，２，２－トリフルオロエチル）－１，２，３，４，５，６，７，８，９，１０，１１，１２，１３，１４－テトラデカヒドロ－［１］オキサ［４，７，１０，１４］テトラアザシクロヘプタデシノ［１６，１７－ｆ］キノリン－３－カルボキサミドの結晶形
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
US20250268979A1 (en) 2022-09-15 2025-08-28 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
KR20150041174A (ko) 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ585880A (en) 2007-12-07 2012-08-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP3345625B1 (en) 2008-08-13 2020-12-09 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
PT2365972E (pt) 2008-11-06 2015-03-31 Vertex Pharma Moduladores de transportadores de cassetes de ligação à atp
MX361711B (es) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
NZ700556A (en) 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
AU2011237368B2 (en) 2010-04-09 2015-07-23 Ekso Bionics Exoskeleton load handling system and method of use
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
SG10201913594UA (en) 2010-04-22 2020-02-27 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
HRP20170754T1 (hr) 2011-05-18 2017-07-28 Concert Pharmaceuticals Inc. Deuterirani derivati ivakaftora
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
HUE070382T2 (hu) 2012-11-02 2025-06-28 Vertex Pharma Gyógyászati készítmények CFTR közvetített betegségek kezelésére
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
IL294042B2 (en) * 2018-02-15 2026-01-01 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11873300B2 (en) * 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
IL314449A (en) * 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis

Also Published As

Publication number Publication date
EP4225761A1 (en) 2023-08-16
WO2022076620A1 (en) 2022-04-14
TW202229299A (zh) 2022-08-01
UY39458A (es) 2022-05-31
US20230374038A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
AR123708A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123709A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123710A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123711A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123707A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123706A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39374A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AR123705A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
CO2022002749A2 (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quística
CO2023007896A2 (es) Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CL2011000919A1 (es) Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
CO2024013546A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39521A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CL2024003058A1 (es) Tratamiento combinado.

Legal Events

Date Code Title Description
FB Suspension of granting procedure